AngioLab안지오랩

AngioLab is a small KONEX-listed biotech with no reported annual financials in the data, and its shares have fallen sharply over the past year.

The shares closed at ₩2,170 on 2026-10-28, giving a market value of about ₩7.9B, and are down 44.4% over one year, though up 22.7% over three months. The data contains no annual or trailing financial results, and valuation multiples are not available, so the business's current earning power cannot be assessed from this pack. The company profile describes a pharmaceutical and biopharmaceutical business in natural-product drugs, antibody drugs and biosimilars, but the filing excerpt does not detail its own products, customers or locations.

What stands out

• Share price is well below its 52-week high of ₩4,635 and sits about 42% above its 52-week low of ₩1,523.
• Over the last 20 days, retail investors were net sellers of about ₩1.0B, while foreign and institutional net flows were zero.
• Foreign ownership is 0.1%, up from 0% sixty days earlier, which is a very small stake.
• Recent filings are mostly insider shareholding reports, a 5%+ holding report, a convertible share conversion exercise on 2026-09-22 and investor relations events.
• No news headlines were provided for the period, so there is no press coverage in this data to weigh.
• Compared with listed peers, the company is far smaller by market value; the peer P/E and P/B figures are not directly comparable to a company with no reported earnings here.

What to watch

• The next filed annual or quarterly financial statements, which are needed to judge revenue, profit and cash position, since none are in this data.
• Further convertible share conversions or insider and 5%+ holding reports, which could signal changes in share count or ownership.
• Any announcements on clinical, product or licensing progress, which the data does not currently describe.